The research development of Chimeric Antigen Receptor T-cells in hematological malignancies / 实用肿瘤学杂志
Practical Oncology Journal
;
(6): 473-476, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-502777
ABSTRACT
In recent years,chimeric antigen receptor T -cells(CAR-T cells)therapy becomes the new rapid development of adoptive tumor immunotherapy .Its main characteristic is to identify specific T cell receptor of tumor antigen by genetic engineering modification and give its targeting ,killing and persistent treatment .The CAR-T was mentioned for the first time in 1989,and has developed to the fourth generation .CD19-CAR-T treatment technique shows activity in phase I clinical trials of multiple research centers .CAR-T therapy is ex-pected as a new way to cure relapse/refractory hematological malignancies .
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Practical Oncology Journal
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS